FDA clears Orthovita's Vitomatrix dental bone graft substitute
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for Orthovita's Vitomatrix, a bone graft substitute that can be used in certain dental procedures. This includes operations to fill, augment or reconstruct periodontal or bony defects of the oral and maxillofacial region. The product is a resorbable porous synthetic scaffold that uses the same technology as the firm's Vitos bone graft substitute line. Vitomatrix could be used in around 375,000 procedures per year in the US, Malvern, Pennsylvania-based Orthovita estimates. The firm is currently evaluating potential commercial partners to distribute the product or license the underlying technology.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.